Skip to content
Medical Health Aged Care

Monash Expert: World Sleep Day – a focus on sleep equity

Monash University < 1 mins read

Today is World Sleep Day and the focus is on sleep equity for global health. Sleep is essential to health, but measurable differences in sleep health persist across populations across the world, creating additional burdens and reinforcing health inequities.

Available to comment: 

 

Dr Prerna Varma, Research Fellow, Turner Institute for Brain and Mental Health, Sleep and Circadian Medicine Laboratory, School of Psychological Sciences

Contact details: +61, 3 9903 4840 or media@monash.edu
Languages known: English, Hindi, Urdu, Punjabi

  • Designing and delivering personalised interventions for sleep health
  • Engaging with organisations, end-users, and communities to design scalable, practical interventions
  • Developing and implementing digital health technology (SleepSync) for shift workers
  • Examining and addressing sleep and mental health in other underserved populations, including caregivers, people living with dementia, and minority populations. 

The following can be attributed to Dr Varma:

“Healthy sleep should be a right, not a privilege. We need to ensure that everyone has awareness and access to resources they need to support better sleep.

“Sleep is one of the three key pillars of health. But many communities experience barriers in achieving good sleep. Addressing these sleep health inequities is necessary to create a healthier society.

“For a long time, we have thought of sleep as an individual thing, but we now know that so many structural factors, from work hours to socio-economic status, impact sleep. We need to be working with communities to address these structural barriers to improve sleep and health.” 

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or media@monash.edu

 

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.